Nob Hill Therapeutics Secures Series A Funding to Advance Breakthrough Respiratory Technologies

On August 6, 2024 Nob Hill Therapeutics (NHT), an early-stage pulmonary medical device and therapeutics company, reported the first close of a $3 million Series A financing round. The round was led by new investor Tramway Venture Partners and included investments from TCA Venture Group and VIC Technology Venture Development (which founded NHT). In connection with the financing, Chris Japp, Managing Partner of Tramway Venture Partners, will join Nob Hill’s Board of Directors. Sima Ghafari of TCA Venture Group will join as a Board Observer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Nob Hill Therapeutics, Inc. (NHT) is developing new technologies and therapies for lung-related diseases that cannot be effectively treated today. The funds will support continued development of Nob Hill’s high-dose respiratory technology and therapeutics, including pre-IND studies.

Chris Japp said, "We are excited to work with the Nob Hill Therapeutics team and add them to the Tramway portfolio. Their respiratory technology and therapeutics have the potential to help millions of patients that currently do not have good treatment options for lung-related diseases."

Noel Greenberger, CEO of NHT, added, "We continue to advance our goal of being the leading provider of high-dose lung delivery solutions. We look forward to working with our investors, who bring not only years of medical device and therapeutic experience, but pulmonary expertise too. With our investors’ support, we can accelerate our drive to address some of the most challenging pulmonary diseases."

NHT has a patent-protected inhalation device technology capable of delivering high therapeutic doses directly to the lung. It is suitable for patients of all ages and inhalation capabilities, including patients with compromised lung function.